跳至主要内容
临床试验/NCT04353401
NCT04353401已完成不适用

Whole Genome Sequencing Analysis of of SARS-CoV-2 Positive Patients

Vanda Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 79 人开始时间: 2020年8月3日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
79
试验地点
1
主要终点
Associations with severity and outcomes

研究概览

简要总结

We aim to better understand the mode of action of COVID-19 in the context of its interaction with the host genome through whole-genome sequencing.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ability and acceptance to provide written informed consent and fluent in English.
  • Men or women between 18-100+ years, inclusive.
  • Willing to comply with study procedures.
  • SARS-CoV-2 positive test result as confirmed by a RT-PCR assay with a sputum or nasopharyngeal sample (either done prior to or at the screening visit).

排除标准

  • 未提供

结局指标

主要结局

Associations with severity and outcomes

时间窗: 3 months

Clinical associations with human and viral genetics

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验